<DOC>
	<DOC>NCT02475109</DOC>
	<brief_summary>The objective of this study is to assess the safety and tolerability of topical ocular PAN-90806 in patients with proliferative diabetic retinopathy.</brief_summary>
	<brief_title>Study of Topical Ocular PAN-90806 in PDR</brief_title>
	<detailed_description />
	<mesh_term>Retinal Diseases</mesh_term>
	<mesh_term>Diabetic Retinopathy</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Aged 18 years or older with type 1 or type 2 diabetes Proliferative diabetic retinopathy (PDR) in study eye retina with or without diabetic macular edema (DME) involving the center of the macula Demonstrate the ability, or have a family member who is willing and able, to instill topical ocular drops in the study eye Current or recent use (within the last 3 months) of antivascular endothelial growth factors (antiVEGF) in either eye; Uncontrolled hypertension despite use of antihypertensive medications Unwillingness to refrain from wearing contact lenses for the duration of the study. Participation in any investigational drug or device study, systemic or ocular, within past 3 months Women who are pregnant or nursing Known serious allergies or hypersensitivity to the fluorescein dye used in angiography or to the components of the PAN90806 formulation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Proliferative Diabetic Retinopathy</keyword>
</DOC>